×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Comparing accelerated approval pathways among EMA, FDA and PMDA
Session Chair(s)
Nobumasa Nakashima
Health Policy Director, National Healthcare Policy Secretariat
Cabinet Office, Japan
This session invites key stakeholders including industry representatives and regulators to actively share the current situation and concerns of early access programs. And subsequently, means to better these programs are discussed.
Speaker(s)
FDA Recent Experience and Perspective on the Accelerated Approval Pathway
Theresa Mullin, PhD
FDA, United States
Associate Center Director - Strategic Initiatives, CDER
Case examples and thoughts on accelerated approval pathways
Taro Ishibashi, PhD, RPh
Pfizer R&D Japan, Japan
President
PRIME, collaboration and evidence by design
Agnès Saint-Raymond, DrMed
European Medicines Agency, Netherlands
Head of Division International Affairs
Have an account?